Teva And Alvotech Celebrate Interchangeability For US Ustekinumab

As Biocon Claims Advantage By Securing Market Access Agreements

 
• By Dave Wallace
  
Interchangeability has been granted for the Selarsdi biosimilar (Shutterstock)

More from Biosimilars

More from Business